FATE
FATE
NASDAQ · Biotechnology

Fate Therapeutics Inc

$1.14
+0.09 (+8.57%)
As of Feb 8, 2:09 PM ET ·
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 39.34M 39.14M 43.52M
Net Income -9,457,413 -10,010,485 -9,808,127
EPS
Profit Margin -24.0% -25.6% -22.5%
Rev Growth +1.5% +22.5% +8.4%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 17.55M 13.35M 16.76M
Total Equity 51.67M 48.97M 54.56M
D/E Ratio 0.34 0.27 0.31
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -15,185,010 -16,322,152 -16,265,725
Free Cash Flow -7,860,846 -10,981,777 -9,671,173